FilingReader Intelligence
Hengrui Medicine gains approval for ankylosing spondylitis drug
April 9, 2025 at 05:10 AM UTC•By FilingReader AI
Jiangsu Hengrui Medicine (SSE:600276) announced today that its subsidiary, Suzhou Shengdiya Biomedical, has received approval from China's National Medical Products Administration for its innovative drug, Funarocimab injection. This new indication expands the drug's use to include the treatment of adult patients with active ankylosing spondylitis who have shown inadequate response to conventional therapies.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime